-
1.发明公开Stabilization of somatotropins and other proteins by modification of cysteine residues 失效通过修饰CYSTEINE残留来稳定SOMATOTROPINS和其他蛋白质
公开(公告)号：EP0458064A3
公开(公告)日：1992-06-17
申请号：EP91106224.8
申请日：1991-04-18
IPC分类号： C07K17/08 , A61K47/48 , C07C233/31 , C07C237/22 , C08G65/32
CPC分类号： C07K1/1077 , A61K38/00 , A61K47/60 , C07C233/18 , C07C237/22 , C07K14/55 , C07K14/61
摘要： The present invention relates to physiologically-active derivatized natural and recombinant mammalian and human proteins and polypeptides. The invention provides chemical methods for derivatizing natural and recombinantly-derived proteins or polypeptides containing cysteine residues, either naturally or through site specific mutageneses. The pharmaceutical compositions containing said derivatized proteins and/or polypeptides are formulated to provide stable, long-acting compositions of such proteins and/or polypeptides, previously difficult to achieve.
-
2.发明公开Stabilization of somatotropins and other proteins by modification of cysteine residues 失效Stabilisierung von somatotropin und anderen Proteinen durch Modifizierung von Cysteinsresten。
公开(公告)号：EP0458064A2
公开(公告)日：1991-11-27
申请号：EP91106224.8
申请日：1991-04-18
IPC分类号： C07K17/08 , A61K47/48 , C07C233/31 , C07C237/22 , C08G65/32
CPC分类号： C07K1/1077 , A61K38/00 , A61K47/60 , C07C233/18 , C07C237/22 , C07K14/55 , C07K14/61
摘要： The present invention relates to physiologically-active derivatized natural and recombinant mammalian and human proteins and polypeptides. The invention provides chemical methods for derivatizing natural and recombinantly-derived proteins or polypeptides containing cysteine residues, either naturally or through site specific mutageneses. The pharmaceutical compositions containing said derivatized proteins and/or polypeptides are formulated to provide stable, long-acting compositions of such proteins and/or polypeptides, previously difficult to achieve.
摘要翻译： 本发明涉及生理活性衍生的天然和重组哺乳动物和人类蛋白质和多肽。 本发明提供用于衍生自然和重组衍生的蛋白质或含有半胱氨酸残基的多肽的化学方法，天然或通过位点特异性突变体。 将含有所述衍生化蛋白质和/或多肽的药物组合物配制成提供以前难以实现的这种蛋白质和/或多肽的稳定的长效组合物。
-
3.发明公开Method of treating or preventing mastitis in animals with involuting mammary glands by administering recombinant cytokines 失效一种用于治疗或预防乳腺炎的动物与更年期乳腺，通过重组细胞因子的灵感方法。
公开(公告)号：EP0537437A2
公开(公告)日：1993-04-21
申请号：EP92113451.6
申请日：1992-08-06
IPC分类号： A61K37/02
CPC分类号： A61K38/2006 , A61K38/193 , A61K38/2013 , A61K45/06
摘要： Cytokines are useful for the ability to improve the natural defense system of the involuting mammary gland. In addition to the immunopotentiating activity, cytokines accelerate the normal physiology of involution of the mammary gland and thereby afford further protection against new infections of mammals. The involuting mammary gland is very susceptible to infection during the early stages of involution and therefore decreasing the period of highest susceptibility while also improving the natural defense mechanisms is of great advantage over most therapies. Used alone, in various cytokine combinations, or in combination with other therapeutics, cytokines protect the mammary gland and cure existing infections and are particularly useful during cessation of lactation and early reinitiating of lactation.
摘要翻译： 细胞因子是改善乳腺消退的自然防御系统的能力是有用的。 除了免疫强化作用，细胞因子促进乳腺复旧的正常生理，从而提供进一步的保护，防止哺乳动物的新的感染。 在消退期乳腺是在退化的早期阶段，因此降低敏感性最高的时期，同时使提高自然防御机制具有很大的优势了大部分治疗感染非常敏感。 单独使用时，在各种细胞因子的组合，或与其他疗法结合，细胞因子保护乳腺和治疗现有的感染，是哺乳期和哺乳期的早期重新开始停止时特别有用。
-
4.发明公开Use of a phagocyte-activating agent : LPS or IL-2 for the manufacture of a medicament for treating staphylococcus aureus infection in cows 失效使用phagozytise每股4物质：LPS或IL-2用于制备药物的用途在牛治疗金黄色葡萄球菌感染。
公开(公告)号：EP0405315A2
公开(公告)日：1991-01-02
申请号：EP90111644.2
申请日：1990-06-20
IPC分类号： A61K38/00
CPC分类号： A61K35/20 , A61K31/739 , A61K38/2013 , A61K38/4886 , A61K45/05 , G01N33/5091 , G01N33/56938 , G01N33/6869
摘要： The present invention relates to methods for treating infectious diseases in animals by initiating qualitative and quantitative changes in the phagocytic cells of said animals. This activation occurs by the administration of a phagocytic-cell activating agent, such as immunomodulators; cytokines such as interleukins (interleukin -1, 2, 3, 4, 5, 6 and 7), interferons and colony stimulating factors; antimicrobials such as mucolytic enzymes, lysozyme, lysostaphin; complement and its components; chemotractants such as lipopolysaccharide and zymosan activated cow sera. The appropriate activation of the phagocytic cells in the animal for effective therapy requires not only an increase in the total number of cells which phagocytose cell particles, but also an increase in the number of particles phagocytosed per cell, intracellular killing. Thus, the present invention also relates to a method for measuring the efficiency of phagocytic-activating agents to predict and monitor appropriate therapy.
摘要翻译： 本发明涉及用于通过发起质变和量变在动物的吞噬细胞，所述处理在动物中感染性疾病。 发生由吞噬细胞活化剂，：如免疫调节剂的施用这种激活的; 细胞因子：例如白细胞介素（白介素1，2，3，4，5，6和7），干扰素和集落刺激因子; 检查作为粘液溶解酶，溶菌酶，溶葡球菌酶的抗微生物剂; 补体及其部件; chemotractants：如脂多糖和酵母聚糖活化的牛血清。 在动物有效治疗的吞噬细胞的适当的激活不仅需要在细胞的总数量，以增加吞噬哪个小区的颗粒，所以但在每个细胞吞噬的粒子，细胞内杀伤的数量增加。 因此，本发明因此涉及用于测量吞噬活化剂的效率预测和监测适当的治疗的方法。
-
5.发明授权Use of a phagocyte-activating agent : LPS or IL-2 for the manufacture of a medicament for treating staphylococcus aureus infection in cows 失效使用phagozytise每股4物质：LPS或IL-2用于制备药物的用途在牛治疗金黄色葡萄球菌感染。
公开(公告)号：EP0405315B1
公开(公告)日：1995-08-23
申请号：EP90111644.2
申请日：1990-06-20
IPC分类号： A61K38/00
CPC分类号： A61K35/20 , A61K31/739 , A61K38/2013 , A61K38/4886 , A61K45/05 , G01N33/5091 , G01N33/56938 , G01N33/6869
-
6.发明公开Improved immunogenicity of a vaccine by incorporation of a cytokine within an immune-stimulating complex containing an antigen 失效通过细胞因子的掺入改善了疫苗的免疫原性，在含有抗原的免疫刺激复合物。
公开(公告)号：EP0604727A1
公开(公告)日：1994-07-06
申请号：EP93117244.9
申请日：1993-10-25
CPC分类号： A61K38/2006 , A61K39/12 , A61K39/155 , A61K39/39 , A61K2039/5252 , A61K2039/552 , A61K2039/55505 , A61K2039/55527 , A61K2039/55555 , A61K2039/55577 , C12N2760/18534
摘要： This disclosure describes a vaccine comprising an effective immunizing amount of an immune-stimulating complex which contains an antigen and a cytokine. The composition may also contain conventional adjuvants, preservatives and a pharmaceutically acceptable carrier. The disclosure further describes a unique method for enhancing or accelerating the immunogenicity of weak antigens by parenterally administering to a mammal an effective immunizing amount of the aforesaid vaccine.
摘要翻译： 本发明描述一种疫苗，其包含在抗原和细胞因子包含免疫刺激复合物的免疫有效量的。 因此，该组合物可以含有常规的佐剂，防腐剂和药学上可接受的载体。 本公开还描述了用于增强或通过胃肠外给予加速弱抗原的免疫原性，以在上述疫苗免疫有效量的哺乳动物的独特方法。
-
7.发明授权
公开(公告)号：EP0458064B1
公开(公告)日：1998-02-25
申请号：EP91106224.8
申请日：1991-04-18
IPC分类号： C07K17/08 , A61K47/48 , C07C233/31 , C07C237/22 , C08G65/32
CPC分类号： C07K1/1077 , A61K38/00 , A61K47/60 , C07C233/18 , C07C237/22 , C07K14/55 , C07K14/61
-
公开(公告)号：EP0609739A1
公开(公告)日：1994-08-10
申请号：EP94100947.4
申请日：1994-01-24
IPC分类号： A61K39/39
CPC分类号： A61K39/092 , A61K38/2006 , A61K39/09 , A61K39/102 , A61K39/39 , A61K2039/552 , A61K2039/55522 , A61K2039/55527 , C12N2710/16734 , C12N2760/18634 , C12N2770/24034 , Y10S424/813 , Y10S424/815 , Y10S424/823 , Y10S424/825
摘要： A method of reversing or preventing immunosuppression or antigenic interference associated with combination vaccines in mammals, is disclosed. Cytokines, or cytokine inhibitors, are administered in conjunction with the combination vaccine. The cytokine or cytokine inhibitor can be administered concurrently with or subsequently to the vaccine, and can be recombinantly produced or isolated from cell culture.
摘要翻译： 公开了一种在哺乳动物中逆转或预防与组合疫苗相关的免疫抑制或抗原干扰的方法。 细胞因子或细胞因子抑制剂与组合疫苗一起施用。 细胞因子或细胞因子抑制剂可以与疫苗同时或随后施用，并且可以从细胞培养物中重组产生或分离。
-
9.发明公开Compositions containing surfactants as potentiating agents for the treatment of mammalian diseases 失效含有表面活性剂的组合物作为治疗哺乳动物疾病的潜在药剂
公开(公告)号：EP0548558A3
公开(公告)日：1993-10-13
申请号：EP92119891.7
申请日：1992-11-23
发明人： Daley, Michael Joseph , Steber, William David , Furda, Gary John , Johnston, Paul Andrew , Oldham, Elizabeth Rae
CPC分类号： A61K47/10 , A61K9/0014 , A61K9/0019 , A61K9/0041 , A61K47/14 , A61K47/26 , A61K47/28
摘要： A therapeutic composition which contains a potentiating or safening amount of an aqueous surfactant in combination with a bactericidal agent and/or a biological response modifier is described herein. The disclosure further describes an improved method for treating mastitis by administering the composition to an afflicted mammal. Additionally, the disclosure describes a method for screening suitable formulations for treating infectious diseases.
-
10.发明公开Method of treating or preventing mastitis in animals with involuting mammary glands by administering recombinant cytokines 失效通过管理重组细胞因子来处理或预防动物中涉及主要动物的主体的方法
公开(公告)号：EP0537437A3
公开(公告)日：1993-12-29
申请号：EP92113451.6
申请日：1992-08-06
IPC分类号： A61K37/02
CPC分类号： A61K38/2006 , A61K38/193 , A61K38/2013 , A61K45/06
摘要： Cytokines are useful for the ability to improve the natural defense system of the involuting mammary gland. In addition to the immunopotentiating activity, cytokines accelerate the normal physiology of involution of the mammary gland and thereby afford further protection against new infections of mammals. The involuting mammary gland is very susceptible to infection during the early stages of involution and therefore decreasing the period of highest susceptibility while also improving the natural defense mechanisms is of great advantage over most therapies. Used alone, in various cytokine combinations, or in combination with other therapeutics, cytokines protect the mammary gland and cure existing infections and are particularly useful during cessation of lactation and early reinitiating of lactation.
-
-
-
-
-
-
-
-
-
搜索结果
12 条记录 (耗时 0.011 秒)
